Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Beone Medicines Ltd's Business Segments
Beone Medicines Ltd's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
16
Largest Segment
Product revenue
Total Revenue
$ 1,513
Regions Reported
2
Revenue Share by Reportable Segment - FY
- Product revenue98.3%
- Product revenue BRUKINSA72.4%
- U S - total revenue51.7%
- Product revenue U S - total revenue50.6%
- Product revenue TEVIMBRA13.6%
- Product revenue XGEVA5.9%
- Product revenue BLINCYTO2.2%
- Product revenue Other2.2%
- Other Revenue1.7%
- Other Revenue Novartis1.7%
- Amgen royalty revenue Novartis1.2%
- Product revenue KYPROLIS1.1%
- Other Revenue U S - total revenue1.1%
- Product revenue POBEVCY0.8%
- Novartis broad markets revenue Novartis0.3%
- Other Novartis0.2%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Product revenue | $ 1,487 | 98.3% |
| Product revenue BRUKINSA | $ 1,095 | 72.4% |
| U S - total revenue | $ 782 | 51.7% |
13 more segments available
Sign in to unlock the full Beone Medicines Ltd dataset.
Revenue Share by Region - FY
- Europe12.8%
- All Other Countries Except China and United States of America4.3%
Revenue by Geographic Region - FY
| Region | Revenue (Millions) | % of Total |
|---|---|---|
| Europe | $ 194 | 12.8% |
| All Other Countries Except China and United States of America | $ 65 | 4.3% |
Revenue by Product & Service Category - FY
- Product98.3%
- Other Revenue1.7%
Revenue by Product & Service Category - FY
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Product | $ 1,487 | 98.3% |
| Other Revenue | $ 26 | 1.7% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Annual Results
Revenue Share by Reportable Segment - FY
- Product revenue98.3%
- Product revenue BRUKINSA72.4%
- U S - total revenue51.7%
- Product revenue U S - total revenue50.6%
- Product revenue TEVIMBRA13.6%
- Product revenue XGEVA5.9%
- Product revenue BLINCYTO2.2%
- Product revenue Other2.2%
- Other Revenue1.7%
- Other Revenue Novartis1.7%
- Amgen royalty revenue Novartis1.2%
- Product revenue KYPROLIS1.1%
- Other Revenue U S - total revenue1.1%
- Product revenue POBEVCY0.8%
- Novartis broad markets revenue Novartis0.3%
- Other Novartis0.2%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Product revenue | $ 1,487 | 98.3% |
| Product revenue BRUKINSA | $ 1,095 | 72.4% |
| U S - total revenue | $ 782 | 51.7% |
13 more segments available
Sign in to unlock the full Beone Medicines Ltd dataset.
Description of Beone Medicines Ltd
The registrant is a global oncology company focused on discovering and developing cancer treatments. In 2025, it reported approximately $5.3 billion in global revenue, representing a 40.2% increase from the prior year, and a net income of $286.9 million. The company specializes in hematology, particularly chronic lymphocytic leukemia (CLL), with three key mechanisms of action: BRUKINSA®, a Bruton’s tyrosine kinase (BTK) inhibitor; sonrotoclax, a B-cell lymphoma 2 (BCL2) inhibitor approved in China for relapsed/refractory mantle cell lymphoma (MCL) and CLL; and BTK chimeric degradation activation compound (BTK-CDAC), BGB-16673, designed to degrade both wildtype and mutant BTK. BRUKINSA is approved in over 75 markets and leads the global market in B-cell malignancies. The company is conducting multiple Phase 3 trials, including combinations of BRUKINSA and sonrotoclax. It also has a solid tumor pipeline with five new molecular entities in clinical development targeting cancers such as breast, lung, and gastrointestinal. The company employs nearly 6,000 clinical and manufacturing staff, operating a global clinical development model that reduces reliance on contract research organizations. Incorporated in Switzerland, it has subsidiaries in the U.S., China, the UK, and Australia, and employs approximately 12,000 people worldwide.
The company operates a single reportable segment focused on pharmaceutical products. The Chief Executive Officer reviews consolidated results for resource allocation and performance evaluation of the company as a whole.